Author:
Mustafa Rawand,Mirza Raouf,Rasool Hemn
Abstract
BackgroundRheumatoid arthritis is a common autoinflammatory disease that affects the joints and causes several extra-articular problems, including ocular involvement, which typically manifests in the anterior ocular region. The anti-CCP has a sensitivity comparable to the rheumatoid factor and higher specificity for identifying the disease.
ObjectivesTo estimate the prevalence of eye involvements in Rheumatoid arthritis and their correlation to the anti-cyclic citrullinated peptide antibody.
Patients and MethodsA cross-sectional study of 121 patients who satisfied the 2010 ACR/EULAR RA Classification Criteria (6/10 or more points) were between 18 and 60. After establishing a patient’s medical history and physical examination, blood samples were collected to test for anti-CCP antibodies, and an eye exam was conducted.
ResultsThere were significantly more females than males;104 (86%) were female, and 17 (14%) were males. The median age was 47(42−53.5) years. The median disease duration was 4(2−10) years. The mean disease activity was 3.86 ±1, and the median anti-cyclic citrullinated antibody titers were 29.18(16.75−133.35) U/ml. The overall eye complications typical of Rheumatoid arthritis were observed in 37 (30.6%) and 84 (69.4%) without eye involvement. Dry eyes were the most frequent eye complaint (29.8%). One instance with episcleritis (0.8%). One with filamentary keratitis (0.8%). Anterior uveitis was detected in two cases (1.7%). Eye involvement correlated with anti-cyclic citrullinated peptide antibody (P- value 0.004).
ConclusionEye manifestations of rheumatoid arthritis were a prominent part of extra-articular manifestation. The dry eye was the most apparent manifestation, and they correlated to the anti-CCP antibody.
Publisher
Journal of Zankoy Sulaimani - Part A
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference41 articles.
1. Van der Woude D, Van der Helm-van Mil AHM. Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol [Internet]. 2018;32(2):174–87. Available from: https://doi.org/10.1016/j.berh.2018.10.005
2. Radu AF, Bungau SG. Management of rheumatoid arthritis: An overview. Cells [Internet]. 2021 Apr 27 [cited 2022 Sep 23];10(11):301–15. Available from: https://www.nature.com/articles/s41584-020-0409-1
3. Lin YJ, Anzaghe M, Schülke S. Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. Cells. 2020;9(4).
4. Jang S, Kwon EJ, Lee JJ. Rheumatoid Arthritis: Pathogenic Roles of Diverse Immune Cells [Internet]. Vol. 23, International Journal of Molecular Sciences. MDPI AG; 2022 [cited 2022 Sep 14]. p. 905. Available from: https://doi.org/10.3390/ijms23020905
5. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet [Internet]. 2016 Oct 22 [cited 2022 Aug 8];388(10055):2023–38. Available from: http://dx.doi.org/10.1016/S0140-6736(16)30173-8